Adverum Biotechnologies, INC 8-K filings

Adverum Biotechnologies, Inc. has completed its merger with Flying Tigers Acquisition Corporation, a wholly-owned subsidiary of Eli Lilly and Company, following a successful tender offer.

Adverum Biotechnologies announced positive two-year follow-up data from its LUNA Phase 2 clinical trial for Ixo-vec in wet AMD, demonstrating significant reduction in injection burden and sustained visual and anatomic control.

Adverum Biotechnologies, Inc. terminated a long-term lease, incurring a $7.4 million promissory note, and announced the completion of patient enrollment for its pivotal Phase 3 ARTEMIS trial for Ixo-vec.

Eli Lilly and Company announced a definitive agreement to acquire Adverum Biotechnologies, Inc. for an upfront cash payment and contingent value rights tied to its lead gene therapy candidate, Ixo-vec.

Adverum Biotechnologies announced accelerated timelines for its pivotal Phase 3 ARTEMIS trial of Ixo-vec for wet AMD, with screening completed ahead of schedule and full enrollment and topline data expected sooner.

Adverum Biotechnologies reports Q2 2025 financial results, highlights strong ARTEMIS Phase 3 trial enrollment, and announces a $10 million private placement.

Adverum Biotechnologies, Inc. announced that its stockholders approved an amended equity incentive plan and the repricing of certain outstanding stock options, including those held by executive officers, at its 2025 Annual Meeting.

Adverum Biotechnologies announces Q1 2025 financial results, highlights pipeline progress including the initiation of the ARTEMIS registrational trial for Ixo-vec in wet AMD, and presents promising long-term data.

Adverum Biotechnologies announces its Q4 and full year 2024 financial results, along with pipeline highlights and updates to anticipated milestones, focusing on its Ixo-vec gene therapy program for wet AMD.

Adverum Biotechnologies announces it will restate financial statements from 2022-2024 due to non-cash errors related to tenant improvement allowances on a North Carolina property lease and sublease.

Adverum Biotechnologies reports positive 52-week results from its LUNA Phase 2 trial and four-year follow-up data from the OPTIC extension trial for Ixo-vec in wet AMD, showcasing significant treatment burden reduction and sustained visual outcomes.

Adverum Biotechnologies announced its third quarter 2024 financial results, provided a corporate update, and highlighted upcoming milestones including 52-week LUNA and 4-year OPTIC data.

Adverum Biotechnologies reports positive interim results for its Ixo-vec gene therapy, selects a dose for Phase 3 trials, and secures FDA RMAT designation.

Adverum Biotechnologies reports positive interim results from its LUNA Phase 2 trial of Ixo-vec for wet AMD, with the 6E10 dose demonstrating a potential best-in-class profile and selected for Phase 3 development.

Adverum Biotechnologies held its 2024 Annual Meeting, electing directors, ratifying the accounting firm, and approving executive compensation and a new equity incentive plan.

Adverum Biotechnologies has appointed Rabia Gurses Ozden as Chief Medical Officer and Szilard Kiss as a new director, effective June 10, 2024, leading to a board reshuffle.

Adverum Biotechnologies announced positive interim results from its LUNA Phase 2 trial for wet AMD and reported a strong cash position to fund operations into late 2025.

Adverum Biotechnologies has executed a 1-for-10 reverse stock split and filed a restated certificate of incorporation, effective March 21, 2024.

Adverum Biotechnologies reported positive preliminary data from its LUNA Phase 2 trial for Ixo-vec in wet AMD, completed a $127.5 million private placement, and announced a 1-for-10 reverse stock split.

Adverum Biotechnologies announced positive preliminary efficacy and safety data from its LUNA Phase 2 trial of Ixo-vec for wet AMD, demonstrating significant reductions in anti-VEGF injections and maintained visual acuity.

Adverum Biotechnologies has agreed to a settlement in a stockholder derivative lawsuit, implementing changes to director compensation policies and practices.

Adverum Biotechnologies has entered into securities purchase agreements to raise $127.8 million through a private placement of common stock and pre-funded warrants.